Global Biologics Contract Development Market Size, Trends & Growth Opportunity, By Source (Microbial, Mammalian, and Others), By Product Service (Cell Line Development, Process Development, Product, and Others), By Disease Indication, By Region and Forec

Global Biologics Contract Development Market Size, Trends & Growth Opportunity, By Source (Microbial, Mammalian, and Others), By Product Service (Cell Line Development, Process Development, Product, and Others), By Disease Indication, By Region and Forecast till 2027.

Global Biologics Contract Development Market

The global Biologics Contract Development market was valued at US$ 9.93 billion in 2021 and it is expected to reach at US$ 18.15 billion in 2027 at a CAGR of 10.8 % during forecast period 2022-2027.

Biologics contract development organizations provide complete services from cell line development to long term commercial supply of biological products. They offer various services including development of cell lines, analytical and bio-analytical methods, upstream and downstream processes, and formulations and quality assessment. This is type of outsourcing where manufacturer enters into formal agreement with another manufacturing organization for its parts, components, and products.

Market Drivers

Rise in adoption of advanced technologies for biological production is the key driving factor which is expected to boost the global biologics contract development market growth. Furthermore, increase in outsourcing of research and development activities by pharma and bio-pharma companies and favourable regulatory environment for clinical trials in developing nations will positively contribute the market growth. Moreover, increase in number of mergers and collaborations will propel the market growth. For instance, in March 2019, Thermo Fischer Scientific had announced that it will acquire Brammer Bio, which is leading viral vector contract developer for cell and gene therapies. The main aim of this acquisition is strengthening its product portfolio in the area of gene therapy. In addition to that, increase in prevalence of various diseases such as cancer, neurological disorders, and cardiovascular diseases will fuel the market growth. For instance, as per the World Health Organization (WHO) approximately 8.2 million people die each year due to cancer worldwide. Many biologics contract organizations are now shifting to Single Use Bioreactors that offer lower up front capital costs, improved throughputs, and greater manufacturing flexibility will drive the biologicas contract development market growth.

Market Restraints

However, change in trade policies between countries is the major challenging factor which is expected to hinder the global biologics contract development market growth during this analysis period.

Covid-19 Impact

Due to outbreak of covid -19 as public emergency and pandemic declared there is increase in demand for medical supplies,the devices like atomizers,life-support machines,oxygen generators,PPE kit which significantly impact the market growth.

Recent Development

In 2021, Almac Group launch of biologics contract of testing and development solutions which helps in development and testing of new biologics products.In 2020, Lake Pharma In, launch integrated chemistry and biologics services for streamlined antibody- drug conjugates development solutions for pharmaceutical and biotechnology sectors.

Market Segmentation

Global Biologics Contract Development Market is segmented into source such as Microbial, Mammalian, and Others, by product service such as Cell Line Development, Process Development (Upstream, and Downstream), product ( MABs, Recombinant Proteins, and Others), and Others. Further, market is segmented into disease indication such as Oncology, Immunological Disorder, Cardiovascular Disorder, Haematological Disorder, and Others.

Also, Global Biologics Contract Development Market is segmented into five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

Market Key Players

Various key players are discussed in this report such as WuXi Biologics, Fujifilm Diosynth Biotechnologies, Abzena Ltd., AGC Biologics, KBI Biopharma, SE Thermo Fisher (Patheon), LakePharma, Genscript Biotech Corporation, Bionova Scientific, and Boehringer Ingelheim BioXcellence etc.

Market Taxonomy

By Source

• Microbial
• Mammalian
• Others

• Cell Line Development
• Process Development
• Upstream
• Downstream
• Product
• MABs
• Recombinant Proteins
• Others
• Others

• Oncology
• Immunological Disorder
• Cardiovascular Disorder
• Hematological Disorder
• Others

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa

• What are the Key Opportunities in Global Biologics Contract Development Market?
• What will be the growth rate from 2022 to 2027?
• Which segment/region will have highest growth?
• What are the factors that will impact/drive the Market?
• What is the competitive Landscape in the Industry?
• What is the role of key players in the value chain?
• What are the strategies adopted by key players?